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Abstract 
Transforming growth factor β (TGF-β) signaling pathway plays important roles in many biological 
processes, including cell growth, differentiation, apoptosis, migration, as well as cancer initiation and 
progression. SMAD4, which serves as the central mediator of TGF-β signaling, is specifically 
inactivated in over half of pancreatic duct adenocarcinoma, and varying degrees in many other types 
of cancers. In the past two decades, multiple studies have revealed that SMAD4 loss on its own does 
not initiate tumor formation, but can promote tumor progression initiated by other genes, such as 
KRAS activation in pancreatic duct adenocarcinoma and APC inactivation in colorectal cancer. In 
other cases, such as skin cancer, loss of SMAD4 plays an important initiating role by disrupting DNA 
damage response and repair mechanisms and enhance genomic instability, suggesting its distinct 
roles in different types of tumors. This review lists SMAD4 mutations in various types of cancer and 
summarizes recent advances on SMAD4 with focuses on the function, signaling pathway, and the 
possibility of SMAD4 as a prognostic indicator. 
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Introduction 
The transforming growth factor-beta (TGF-β) 
superfamily contains over forty members, including 
TGF-βs, Nodal, Activin, and bone morphogenetic 
proteins (BMPs) [1, 2]. TGF-β/SMAD4 signaling 
pathway controls the signal transduction from cell 
membrane to nucleus, and is responsible for a wide 
range of cellular processes, including proliferation, 
differentiation, apoptosis, migration, as well as cancer 
initiation and progression [3]. TGF-β protein has dual 
functions on tumorigenesis where it exhibits a 
suppressive role by inducing cell cycle arrest and 
apoptosis at early stages of tumor formation. Later on, 
with tumor progression, tumor cells gradually 
become insensitive to it, and secreted TGF-β protein 
enhances tumor immunosuppression and facilitates 
tumor angiogenesis, invasion and metastasis [1]. As 
the core mediator of canonical TGF-β signaling 
pathway, SMAD4 plays a pivotal role in the switch of 
TGF-β function on tumorigenesis. Although the 
TGF-β/SMAD4 pathway is relatively simple, it can be 
regulated extensively by numerous classical 
pathways, such as MAPK, PI3K/AKT and 
WNT/β-catenin, to form a complex network [1, 4]. 
Here, we will review TGF-β/SMAD4 function, its 
related signaling network, and the impact of SMAD4 
mutation on cancer.  
Structure of SMAD4 
SMAD4 gene consists of 12 exons and 10 introns. 
At first, only 11 exons were identified, and another 
exon was discovered years later upstream of exon 1, 
and was therefore named exon 0 [5, 6]. The protein 
encoded by this gene is composed of 552 amino acids, 
with a molecular weight of 60 KD. The primary 
structure of SMAD4 protein consists of three major 
parts, including the N-terminal MH1 domain, the 
C-terminal MH2 domain and the linker region 
between them (Figure 1A) [7]. The MH1 domain is 
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responsible for DNA binding by recognizing the 
SMAD-binding DNA element (SBE) [8], while the 
MH2 domain is important for its transcriptional 
activity [9-11], and can interact directly with the MH1 
domain of other SMAD proteins [12]. The SMAD 
activation domain (SAD), locating at the C-terminal of 
linker region, is necessary for SMAD4 transcriptional 
activity [9]. 
The role of SMAD4 in TGF-β signaling 
pathway 
SMADs are a group of proteins transducing 
extracellular signals directly to the nucleus. There are 
eight different SMADs in mammalian cells, which can 
be divided to three categories: (1) the receptor- 
regulated SMAD (R-SMAD) including SMAD1, 
SMAD2, SMAD3, SMAD5, and SMAD8/9. While 
SMAD2/3 mainly mediate signaling from TGF-β 
subfamily members, SMAD1/5/8 transduct signaling 
from bone morphogenic protein (BMP) subfamily 
members; (2) the common-mediator SMAD 
(Co-SMAD) including only SMAD4, which is the 
central mediator of both TGF-β and BMP signaling 
pathway; and (3) the inhibitory SMAD (I-SMAD) 
including SMAD6 and SMAD7, which mainly 
function to inhibit receptor mediated R-SMAD 
phosphorylation, thus preventing the complex 
formation with Co-SMAD [13] (Figure 1B). Because 
many members in both TGF-β and BMP subfamilies 
play many important roles in various cancers, it is out 
of scope to describe specific functions of members in 
each of these subfamilies, therefore we will use 
TGF-β/SMAD4 to represent SMAD4 mediated 
signaling of the superfamily with an emphasis on 
signaling of TGF-β subfamily members. 
 
 
Figure 1. The structure of SMAD4 and its role as the common mediator for signaling of TGF-β superfamily. (A) Diagrammatic representation 
of the structure of SMAD4. Abbreviations: NLS, nuclear localization signal; NES, nuclear export signal; SAD, SMAD activation domain; SBE, SMAD binding DNA 
element. (B) Diagram showing SMAD4 as the common mediator for TGF-β and BMP signaling. TF: transcriptional factor. 
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Figure 2. Schematic diagram of the interaction between TGF-β/SMAD4 signaling pathway and MAPK (mitogen-activated protein kinase), 
PI3K/AKT (phosphatidylinositol-3 kinase/AKT) and WNT/β-catenin pathways. The canonical TGF-β/SMAD4 signal initiates from the TGF-β ligand 
activation and its binding to the type II and I receptors (T-βR II and T-βR I), which then phosphorylates SMAD2/3. The phosphorylated SMAD2/3 form a 
heterodimeric complex with SMAD4 and translocate to the nucleus and bind to SBE directly and regulate target genes transcription with the help of transcriptional 
factors. These target genes are mainly involved in growth arrest and apoptosis. (A) RAS/RAF/ERK1/2 axis regulates the TGF-β/SMAD4 pathway by (1) 
phosphorylating SMAD2 and SMAD3 to prevent its translocation into the nucleus; (2) mediating SMAD4 degradation; and (3) promoting AP-1 complex formation at 
the TGF-β1 promoter, thus boost the TGF-β1 transcription and secretion. As the substrate of JNK, c-Jun can directly bind to the transcriptional corepressor 
TG-interacting factor (TGIF) to inhibit SMAD2 dependent transcription. P38 can phosphorylate SMAD binding partners, such as activating transcription factor-2 
(ATF-2), in nucleus and therefore facilitates TGF-β/SMAD4 induced genes transcription. (B) PI3K/AKT pathway suppresses the T-βR I mediated SMAD3 
phosphorylation through its downstream molecule mTOR. AKT can directly phosphorylate FOXO and keep it in the cytoplasm to prevent its binding to the 
promoter of p27 and p21, thus blocks the TGF-β/SMAD4 mediated cytostatic signals. (C) β-catenin destruction complex consisting of AXIN, APC, GSK3β and CKIα 
causes SMAD7 ubiquitination and degradation. And in turn, SMAD7 can disassemble the complex by binding to AXIN, hence stablize β-catenin and promote its 
nucleus translocation. 
 
TGF-β subfamily signaling initiates from TGF-β 
ligand activation and its binding to the type II 
receptor (T-βR II). T-βR II then recruits and 
phosphorylates the type I receptor (T-βR I), which in 
turn phosphorylates its downstream target 
SMAD2/3. SMAD2/3 are phosphorylated at their 
conserved C-terminal SSXS motif (S is serine and X is 
any amino acid), leading to a conformational change 
in MH2 domain and its subsequent dissociation from 
the receptor [14]. Thereafter, the phosphorylated 
SMAD2/3 form a heterodimeric complex with 
SMAD4, and subsequently translocates to the nucleus 
[13, 15], where it binds to SBE directly and recurits 
co-transcriptional factors to transactivate or repress 
target genes [16]. 
The canonical TGF-β/SMAD4 signaling 
pathway plays a tumor suppressive role at early 
stages, mainly by inducing cell cycle arrest and 
apoptosis. SMAD4 functions at the G1/S checkpoint 
to make cells stay at the G1 phase, thus leading to cell 
cycle arrest [17]. Some CDK inhibitors, like p15, p21 
and p27, are involved in this process [18]. For 
example, SMAD2/3/4 form a complex with 
transcriptional factor FoxO to promote transcription 
of p15 and p21. When ectopic overexpression of 
SMAD4 is induced in SMAD4-negative cells, it can 
bind to the promotor of p21 and enhance its 
transcription [19]. Inversely, TGF-β cannot induce the 
expression of p21 in pancreatic cancer cell lines, which 
lack SMAD4, with the result that cell growth is out of 
control [20]. Additionally, Lecanda et al. (2009) found 
that TGF-β/SMAD4 signal can enhance p27 
expression, whereas inhibition of p27 by siRNA 
blocks the TGF-β/SMAD4 related cell growth arrest 
[21]. 
The nucleus localized SMAD2/3/4 complex 
induces apoptosis by promoting pro-apoptotic genes 
expression, such as TIEG (TGF-β-inducible early 
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response gene), DAPK (the death-associated protein 
kinase), GADD45β and Bim. It was shown that 
expression of TIEG induced by TGF-β signaling 
causes apoptosis in pancreatic epithelial cells [22]. The 
rest three genes were reported to induce cytochrome 
C release from mitochondria and cause caspase 
activation [23-25]. 
Crosstalk with other pathways 
In the past two decades, increasing number of 
classical pathways has been reported to interact with 
the canonical TGF-β/SMAD4 pathway. These 
crosslinks are along the whole TGF-β/SMAD4 signal 
transmision chain, from SMAD2/3 phosphorylation, 
SMAD complex formation, its translocation to nucleus 
and transcriptional activity. Here we will summarize 
the interaction between TGF-β/SMAD4 pathway 
with some well-established pathways including, but 
not limited to, MAPK (mitogen-activated protein 
kinase), PI3K/AKT (phosphatidylinositol-3 
kinase/AKT) and WNT/β-catenin pathways. 
MAPK pathway 
MAPK is a superfamily that transduces 
extracellular signals to nucleus rapidly to regulate 
genes transcription, and affects a wide range of 
cellular processes including cell proliferation, 
differentiation and apoptosis. MAPK consists of three 
principal subfamilies: (1) the extracellular signal 
regulated kinase (ERK1/2); (2) c-Jun N-terminal 
kinase (JNK1/2/3) and (3) P38/MAPKs [26]. These 
subfamilies can phosphorylate a set of proteins to 
alter cell behaviors, and in verse, they can be activated 
by multiple extracellular molecules, such as TGF-β 
cytokines [27]. 
ERK pathway 
ERK pathway is mainly responsible for cell 
growth and survival [28]. It can be activated by the 
RAS/RAF/MEK1/2 axis propagated signal that is 
initiated by membrane-associated receptor tyrosine 
kinases (RTKs) [29]. TGF-β peptide can mediate ERK 
activation rapidly in normal epithelial cells and in 
cancer cells [30]. It has been demonstrated that this 
regulation depends on the T-βR I recruited and 
activated ShcA/Grb2/Sos complex, which subseque-
ntly activate RAS/RAF/MEK1/2 signal [31, 32]. 
Inversely, ERK pathway inhibits the TGF-β/SMAD4 
pathway by phosphorylating SMAD2 and SMAD3 at 
the serine or threonine residues in the linker region, 
thus preventing its translocation into the nucleus [33]. 
Subsequently, Matsuura et al. (2005) identified ERK 
phosphorylation sites in SMAD3 at Thr178, Ser203, 
and Ser207 in lung epithelial cells [34]. The TGF-β 
activated RAS/ERK cascade also promotes AP-1 
complex formation at the TGF-β1 promoter, thus 
boosting the TGF-β1 transcription and secretion [35]. 
SMAD7, as the inhibitory SMAD, can be upregulated 
by ETS transcription factor ER81 through the 
HER2/Neu/ERK pathway in breast and ovarian 
cancer cell lines [36]. However, SMAD7 transcription 
is negatively regulated by ERK cascade in normal rat 
kidney (NRK) fibroblasts, suggesting the cell type 
dependence. 
JNK pathway 
JNK, as a stress-induced kinase, is responsive to 
various stress stimuli and is responsible for multiple 
cellular activities such as proliferation and apoptosis 
[37]. Principally, T-βR I can interact with TRAF6 and 
cause its autoubiquitylation, which subsequently 
activates TAK1 and JNK pathway [38]. Inversely, JNK 
is implicated to reduce the secretion of TGF-β1, as 
upon JNK inactivation, RAS gains ability to induce 
TGF-β1 autocrine [39]. JNK can also mediate 
phosphorylation of SMAD3 in the linker region and 
facilitate its activation by T-βR I, as well as nuclear 
translocation [40]. SMAD2 is another target of JNK, as 
it has been demonstrated that C-Jun, the substrate of 
JNK, can directly bind to the transcriptional 
corepressor TG-interacting factor (TGIF) to inhibit 
SMAD2 dependent transcription [41].  
P38 
Like JNK, p38 is also a stress-induced kinase that 
activated by various stress stimuli and accounts for 
diverse cellular processes. p38 can also be induced by 
TGF-β via T-βR I-TRAF6 interaction and TAK1 
activation [38], and TGF-β induced P38 activation can 
strongly enhance SMAD4 sumoylation by PIAS 
family of E3 ligase, thus facilitating SMAD4 
dependent transcription [42]. In human breast cancer 
cell line, SMAD2/3, phosphorylatd at Ser203/207 by 
Rho-dependent kinase (ROCK) and p38, synergize 
with TGF-β to induce cell growth arrest [43]. Apart 
from the crosstalk in cytoplasm, p38 also 
phosphorylates SMAD binding partners in nucleus 
and therefore affects TGF-β/SMAD4 induced genes 
transcription. For example, as the nuclear target of 
p38, activating transcription factor-2 (ATF-2) could be 
phosphorylated and bind to SMAD4 to activate TGF-β 
induced transcription [44]. 
PI3K/AKT pathway 
PI3K/AKT pathway is an intracellular signaling 
pathway that is usually related to cell proliferation 
and apoptosis inhibition, and is important for the 
initiation and progression of many malignancies [45]. 
Upon activation of RTKs by a ligand, PI3K is activated 
and converts phosphatidylinositol-4,5-bisphosphate 
(PIP2) to phosphatidylinositol-3,4,5-triphosphate 
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(PIP3), which then phosphorylates and activates AKT, 
and makes it localize on the plasma membrane [46]. 
The tumor suppressor PTEN can counteract PI3K and 
thereby alleviate AKT activation [47]. 
A multitude of studies have indicated that 
PI3K/AKT pathway is involved in TGF-β/SMAD4 
pathway regulation. In mammary epithelial cell 
NmuMG, TGF-β1 administration induces AKT 
phosphorylation at Ser473 immediately, and 
transfection of dominant negative Rho inhibits this 
process [48]. Inactivating PI3K/AKT pathway by 
inhibitors affects TGF-β mediated EMT and cell 
migration [48]. This process is also affected by the 
TGF-β1 induced miR-487a overexpression, which 
directly binds to MAGI2 (Membrane-associated 
guanylate kinase inverted 2), and then stabilizes 
PTEN and suppresses PI3K/AKT pathway [49]. 
SMAD3 has been demonstrated to be the target of 
PI3K/AKT to affect TGF-β/SMAD pathway. 
Overexpression of AKT suppresses the T-βR II 
mediated SMAD3 phosphorylation, while the SMAD2 
is not affected [50]. Treatment with rapamycin to 
activate the mammalian target of rapamycin (mTOR), 
which is the downstream of AKT, can suppress 
SMAD3 phosphorylation and activation [50]. 
Meanwhile, PI3K/AKT can also regulate SMAD3 
function by phosphorylating some nuclear 
transcriptional factors, such as FOXO. AKT can 
directly phosphorylates FOXO and keep it in the 
cytoplasm [51]. Once dephosphorylated, FOXO enters 
the nucleus and binds to the promoter of p27 and p21 
as a transcriptional factor, thus facilitating the 
TGF-β/SMAD4 mediated cytostatic signals [52]. 
WNT/β-catenin pathway 
WNT is a type of secretory protein that initiates 
WNT/β-catenin signal from cell membrane to 
nucleus. WNT can bind to Frizzled family receptor 
(FZ) and pass the signal to Dishevelled (DVL) protein 
inside the cell and subsequently to the β-catenin 
destruction complex consisting of AXIN, APC, GSK3β 
and CKIα [53, 54]. The crosstalk between 
TGF-β/SMAD and WNT/β-catenin pathway mainly 
occurs in the nucleus, where SMADs form a complex 
with β-catenin and LEF protein to synergistically 
regulate a set of genes. For example, deletion of 
SMAD4 in the Müllerian duct led to reduced LEF1 
signal, suggesting the alleviated WNT/β-catenin 
signaling pathway [55]. Meanwhile, these two 
pathways reciprocally regulate each other’s ligand 
production and thus influence the pathway initiation 
[56, 57]. In the cytoplasm, SMAD7 is one of the points 
that link the two pathways. It is well known that 
SMAD7 functions to compete with SMAD2/3 for 
receptors, which leads to ubiquitination and 
degradation of receptors, and hence inhibiting 
SMAD2/3 phosphorylation and activation [3]. 
However, SMAD7 is found to disassemble the 
β-catenin destruction complex by binding to AXIN, 
thus stablizing β-catenin and promoting its nucleus 
translocation [56]. Meanwhile, the interaction also 
leads to SMAD7 ubiquitination and degradation by 
E3 ubiquitin ligase Arkadia [57]. Moreover, in the 
human pancreatic adenocarcinoma cells BxPC3, in 
which SMAD4 is homozigously deleted, chronic EGF 
stimulation induces β-catenin phosphorylation that 
can be antagonized by SMAD4 restoration, suggesting 
that SMAD4 homozigous deletion is critical to EGF 
induced WNT/β-catenin signaling pathway 
inhibition [58]. 
TGF-β/SMAD4 in cancer 
It is a common view that cancer is a notorious 
disease with an accumulation of critical genes 
alteration [59]. Heterozygous or homozygous deletion 
of SMAD4 was first discovered in pancreatic duct 
adenocarcinoma, and later detected in various types 
of cancers, such as colorectal cancer, cholangiocarcin-
oma, gastric cancer, prostate cancer and many others, 
though with lower frequencies to some extent (Table 
1). Representative SMAD4 mutations in various 
cancers are summaried in Figure 3. 
Pancreatic cancer 
Pancreatic cancer is a lethal disease with a 5-year 
survival rate of about 8%, and advance is slow for 
treatment [60]. So many studies have demonstrated 
that SMAD4 alteration is closely related with 
pancreatic cancer since its discovery in 1996. Loss of 
heterozygosity occurs in almost 60% human 
pancreatic cancers, and about 50% shows homoz-
ygous deletion or intragenic inactivating mutations [5, 
61]. A further study revealed that SMAD4 mutation 
was associated with pancreatic pathologic stages. The 
inactivation of SMAD4 was 31% (9/29) in the 
high-grade stage neoplasms (Pan IN-3), while none 
was found in the rest 159 low-grade lesions (Pan IN-1 
and 2) [62]. Genetically engineered mouse models 
have been used to investigate the mechanism (Table 
3). Although knockout of SMAD4 by 
pancreatic-specific PDX1-Cre or P48-Cre did not 
initiate pancreatic cancer in mice [63, 64], they 
markedly facilitated tumor progression initiated by 
KRASG12D activation [65] or PTEN inactivation [66]. 
These reports favor the view that SMAD4 has a tumor 
suppressive function at the progressive stage. 
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Figure 3. Schematic diagram of mutational pattern in exons of SMAD4. Note: SMAD4 gene contains 12 exons, 11 of which were identified at first, and 
another exon was discovered later at the upstream of exon 1, so it was called exon 0. The exon 11 is about fifty times longer than exon 10, so it is labeled with dash 
line. 
 
Table 1. SMAD4 genetic alteration frequency in human cancers  
Cancer type Total alteration 
frequency 
Alteration type Sample 
number Complete deletion Amplification Mutation Multiple alterations 
Ampullary Carcinoma 18.1% (29 cases)   18.1% (29 cases)  160 
Bladder Urothelial Carcinoma 1.5% (4 cases)   1.1% (1 cases) 0.4% (1 cases) 276 
Breast Cancer 2.1% (98 cases) 0.7% (33 cases) 0.4% (17 cases) 0.5% (22 cases) 0.6% (26 cases) 4728 
Cholangiocarcinoma 4.2% (2 cases)   4.2% (2 cases)  48 
Colorectal Adenocarcinoma 13.2% (167 cases) 0.9% (11 cases)  12.1% (152 cases) 0.3% (4 cases) 1261 
Desmoplastic Melanoma 10% (2 cases)   10% (2 cases)  20 
Esophageal Adenocarcinoma 8.2% (12 cases)   8.2% (12 cases)  146 
Esophageal Carcinoma 16.8% (31 cases) 9.8% (18 cases)  6% (11 cases) 1.1% (2 cases) 184 
Esophagus-Stomach Cancers 20.8% (55 cases) 10.9% (29 cases) 0.4% (1 cases) 8.3% (22 cases) 1.1% (3 cases) 265 
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma 4.2% (2 cases)  4.2% (2 cases)   48 
Gallbladder Carcinoma 3.1% (1 cases)   3.1% (1 cases)  32 
Glioblastoma 0.7% (5 cases)  0.1% (1 cases) 0.6% (4 cases)  708 
Advanced Germ Cell Tumors 0.6% (1 cases)   0.6% (1 cases)  180 
Hepatocellular Carcinomas 1.2% (10 cases) 0.2% (2 cases)  0.8% (7 cases) 0.1% (1 cases) 840 
Head and Neck Squamous Cell Carcinoma 6.2% (55 cases) 3.8% (34 cases)  2.4% (21 cases)  889 
Recurrent and Metastatic Head & Neck Cancer 1.5% (2 cases)   1.5% (2 cases)  132 
Kidney Cell Carcinoma 0.8% (9 cases) 0.3% (3 cases) 0.1% (1 cases) 0.5% (6 cases)  1198 
Kidney Chromophobe 1.5% (1 cases) 1.5% (1 cases)    65 
Adrenocortical Carcinoma 1.1% (1 cases) 1.1% (1 cases)    88 
Pan-Lung Cancer 4.5% (52 cases) 1.3% (15 cases) 0.1% (1 cases) 3.1% (35 cases) 0.1% (1 cases) 1144 
Lung Adenocarcinoma 4.1% (33 cases) 1% (8 cases) 0.1% (1 cases) 2.5% (20 cases) 0.5% (4 cases) 805 
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Cancer type Total alteration 
frequency 
Alteration type Sample 
number Complete deletion Amplification Mutation Multiple alterations 
Lung Squamous Cell Carcinoma 2.6% (19 cases) 0.7% (5 cases) 0.3% (2 cases) 1.8% (13 cases)  733 
Small Cell Lung Cancer 3.4% (3 cases)   3.4% (3 cases)  139 
NSCLC young adult patients 7.3% (3 cases)   7.3% (3 cases)  41 
Mesothelioma 1.1% (1 cases) 1.1% (1 cases)    87 
Oral Squamous Cell Carcinoma 5% (2 cases)   5% (2 cases)  40 
Ovarian Serous Cystadenocarcinoma 1.3% (4 cases) 0.3% (1 cases) 0.9% (3 cases)   316 
4.8% (15 cases) 3.9% (12 cases) 1% (3 cases)   311 
Pheochromocytoma and Paraganglioma 0.6% (1 cases)  0.6% (1 cases)   162 
Pancreatic cancer 27.8% (206 cases) 6.2% (46 cases)  20.4% (151 cases) 1.2% (9 cases) 740 
Acinar Cell Carcinoma of the Pancreas 26.1% (6 cases)   26.1% (6 cases)  23 
Pancreatic Neuroendocrine Tumors 1% (1 cases)   1% (1 cases)  98 
Pediatric Ewing Sarcoma 1% (1 cases)   1% (1 cases)  105 
Prostate Cancer 1% (5 cases) 0.2% (1 cases)  0.8% (4 cases)  501 
Prostate Adenocarcinoma 2.1% (36 cases) 0.9% (15 cases) 0.5% (8 cases) 0.8% (13 cases)  1678 
Prostate Adenocarcinoma, Metastatic 4.9% (3 cases) 1.6% (1 cases) 1.6% (1 cases)  1.6% (1 cases) 61 
Neuroendocrine Prostate Cancer 10.3% (11 cases)  10.3% (11 
cases) 
  107 
Skin Cutaneous Melanoma 2.5% (3 cases)   2.5% (3 cases)  121 
Cutaneous squamous cell carcinoma 10.3% (3 cases)   10.3% (3 cases)  29 
Sarcoma 3.4% (11 cases) 0.8% (2 cases) 3.4% (9 cases)   450 
Stomach Adenocarcinoma 10.9% (99 cases) 3.7% (34 cases) 0.2% (2 cases) 6% (55 cases) 0.9% (8 cases) 910 
Testicular Germ Cell Cancer 1.3% (2 cases) 0.7% (1 cases)  0.7% (1 cases)  149 
Uterine Carcinoma 3.7% (28 cases) 1.1% (8 cases) 0.3% (2 cases) 2.4% (18 cases)  751 
Modified from http://www.cbioportal.org/index.do. 
 
Table 2. Examples of the studies on SMAD4 and prognosis in pancreatic duct adenocarcinoma. 
Number 
of 
samples 
Sex 
(female/
male) 
Age Stage 
(I-II/III-IV) 
Margin 
(negative/ 
positive) 
N 
(N0/ N1) 
Differentiation 
(well+moderate/poor) 
SMAD4 
(negative/positive) 
Median survival 
(months, SMAD4 
negative/positive) 
P 
value 
Reference 
45 18/27 61 NS 25/20 24/21 33/12 35/10 6.4/13.6 0.0257 [109] 
25 12/13 54.6 10/15 22/3 19/6 25/1 8/17 5/10  0.001 [118] 
249 110/139 65.4 ± 
10.5 
59/190 168/80 NS NS 138/111 14.7/19.2  0.03 [110] 
34 12/22 55.2 ± 
11.3 
18/16 NS 20/14 NS 8/26 6.9/10.6  0.879 [119] 
89 46/43 65.3 
±10.5 
NS 58/31 18/71 55/34 40/49 11.5/14.2 0.006 [120] 
 
Table 3. Examples of SMAD4-deficient mouse models. 
Tissue type   Cre SMAD4 status Combined mutation Phenotypes Reference  
Germline knockout 
Homozygous Deletion  _ SMAD4-/- _ Embryonically lethal [77] 
 
Heterozygous Deletion 
_ SMAD4+/- _ Gastric and duodenal Polyps [77, 78] 
_ SMAD4+/- APC+/- Intestinal Tumorigenesis  [79] 
Tissue-specific knockout 
 
 
Pancreatic progenitor cells 
PDX1-Cre  SMAD4co/co _ No obvious phenotype in pancreas  [65] 
PDX1-Cre  SMAD4co/co KRASG12D IPMN [65, 121] 
PDX1-Cre  SMAD4co/co PTENco/co Accelerated tumor formation  [66] 
 
Pancreatic exocrine progenitor 
P48-Cre SMAD4co/co KRASG12D Enhanced IPMN development [65] 
P48-Cre SMAD4+/co KRASG12D Mucinous cystic neoplasm [122] 
 
Hepatocytes and bile duct 
epithelial cells  
ALB-Cre SMAD4co/co _ Increased iron accumulation in the liver  [123] 
ALB-Cre SMAD4co/co PTENco/co Intrahepatic cholangiocellular carcinoma [67] 
 
Prostate epithelial cells 
PB-Cre4 SMAD4co/co _ No prostate neoplasia [83] 
PB-Cre4 SMAD4co/co PTENco/co Accelerated progression and metastasis to lymph 
nodes and lung 
[83] 
Epidermis and hair follicles MMTV-Cre SMAD4co/co _ Hair follicle defects and squamous cell carcinoma 
formation 
[86, 87] 
Mammary epithelial cells MMTV-Cre SMAD4co/co _ Breast squamous cell carcinoma [124] 
Esophageal and forestomach 
epithelia 
K5-Cre SMAD4co/co _ 19% of mice developed forestomach squamous cell 
carcinoma by 4 months 
[88] 
K5-Cre SMAD4co/co PTENco/co All mice developed forestomach squamous cell 
carcinoma by 2 months 
[88] 
Gastric LGR5+ stem cells LGR5-CreERT2 SMAD4co/co PTENco/co Invasive intestinal-type gastric cancer by 3 months [89] 
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Cholangiocarcinoma  
Cholangiocarcinoma is a type of liver cancer 
originating from the bile duct. Although its prognosis 
is poor compared with that of hepatocellular 
carcinoma, few studies exist to address the molecular 
mechanism. SMAD4 has been regarded as a tumor 
suppressor in cholangiocarcinoma [67]. Loss of 
SMAD4 was noted in 19 of 42 (45.2%) cases with 
intrahepatic cholangiocarcinoma (ICC), and had a 
positive correlation with clinical stages (25% negative 
in stage I and II vs. 58% in stage III and IV) [68]. 
Additionally, loss of SMAD4 was inversely related 
with its prognosis [69]. Hepatolithiasis is commonly 
regarded as a risk factor for cholangiocarcinoma. One 
group examined SMAD4 deletion frequency in the 
normal intrahepatic bile duct (IHD), stone-containing 
IHD and ICC, with the result of 0% (0/24), 4.4% 
(2/46) and 33.3% (3/9) respectively, suggesting that 
loss of SMAD4 promotes transition from IHD to ICC 
[70]. However, tissue-specific deletion of SMAD4 
along in mouse hepatocytes and bile duct epithelial 
cells did not cause discernable tumor formation. But 
homozygous deletion of both SMAD4 and PTEN in 
mouse liver induced intrahepatic cholangiocarcinoma 
[67]. Underlining the phenotype, PTEN and SMAD4 
regulate each other through a negative feedback loop, 
therefore they can compensate each other’s deletion. 
So far, little is known about the mechanism of SMAD4 
in cholangiocarcinoma and more research studies 
examining this are required. 
Colorectal cancer 
The role of SMAD4 in colorectal cancer is similar 
to that in pancreatic cancer and cholangiocarcinoma. 
Accumulation of evidence has confirmed that the loss 
of SMAD4 in colorectal cancer occurs at a frequency of 
about 30% [71]. Royce et al examined SMAD4 
expression by immunohistochemistry and RT-PCR in 
109 patients with early-onset colorectal cancer, and 
detected 27 cases (accounting for 25%) had SMAD4 
loss [72]. A study on colon cancer cell lines HCT116 
and SW620 demonstrated TGF-β administration could 
activate ERK and P38 pathways and induce VEGF 
overexpression when SMAD4 was knocked down 
[73]. In addition, the SMAD4 loss was responsible for 
resistant to 5-fluoruracil mediated apoptosis in these 
two cell lines [73]. The rate of SMAD4 loss has a 
positive correlation with colorectal cancer 
progression, convincing that inactivation of SMAD4 is 
a late event in colorectal carcinogenesis [74, 75]. 
Although germline loss of SMAD4 in human [76] or 
heterozygous deletion in mice [77, 78] caused juvenile 
polyposis (JP), the risk of carcinoma is low and 
associated with a long latency, suggesting that 
SMAD4 loss alone may be insufficient for tumor 
initiation. It has been reported that heterozygous 
deletion of SMAD4 promotes progression of 
colorectal cancer initiated by germline mutation of 
APC [79]. SMAD4 status is also correlated with tumor 
microenvironment. SMAD4-deficient colorectal 
tumor cells secreted more CCL9 and CCL15, 
chemokines that recruit CCR1+ myeloid cells through 
CCL9-CCR1 and CCL15-CCR1 axis, leading to 
metastasis [80, 81]. Moreover, deletion of SMAD4 in 
human colorectal tumor cells reduced the number of 
S100A8-positive monocytes and attenuated the 
sensitivity of tumor cells to chemokine S100A8, 
suggesting the effect of SMAD4 on monocyte infiltrate 
[82]. 
Other cancers 
SMAD4 loss occurs prevalently in above 
mentioned types of cancers and many other cancers 
with lower frequencies (Table 1). Similar to pancreatic 
and intrahepatic cholangiocarcinoma, prostate 
specific deletion of SMAD4 did not initiate cancer 
formation, but synergistically promotes tumorigen-
esis together with PTEN deletion [83]. SMAD4 
mutations are rare in human prostate cancer, but 
SMAD4 promotor methylation is commonly detected, 
which may reduce SMAD4 expression [84]. Of note, 
SMAD4 downregulation was found at an early stage 
in human HNSCC, and deletion of SMAD4 alone in 
murine head and neck epithelia results in 
spontaneous HNSCC that mimics human HNSCC 
[85]. Keratinocyte-specific deletion of SMAD4 results 
in predominantly well-differentiated skin tumors, 
revealing that SMAD4 is a tumor initiator [86]. A very 
similar phenotype is obtained in the mouse mammary 
tumor virus (MMTV)-Cre mediated SMAD4 deletion 
[87]. In these types of cancers, SMAD4 loss occurs 
prior to tumor formation, and disrupts DNA repair 
mechanisms to enhance genomic instability and 
inflammation [85]. It was also reported that mice 
carrying K5-Cre mediated deletion of SMAD4 in 
keratinocytes developed forestomach squamous cell 
carcinoma (SCC) at 8 months, while deletion of PTEN 
only suffered dysplasia. However, concurrent 
deletion of SMAD4 and PTEN led to invasive SCC in 2 
months [88]. Moreover, deletion of SMAD4 and PTEN 
by LGR5-Cre drived gastric LGR5+ stem cells 
transformation, thus causing invasive intestinal-type 
gastric cancer [89]. In the gastric cancer cell lines 
MGC-803 and BGC-823, SMAD4 serves as the direct 
target of miR-324-3p, which promotes gastric cancer 
progression. This miR-324-3p induced tumor growth 
can be rescued by restoration of SMAD4 [90]. These 
data prompt us to conclude that the role of SMAD4 on 
cancer initiation may be cancer type-dependent (Table 
3). 
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TGF-β/SMAD4 in 
epithelial-mesenchymal transition  
Epithelial-mesenchymal transition (EMT) is a 
well-coordinated process that epithelial cells lose their 
cell junctions and polarity, and are transformed to 
mesenchymal cells with the migratory and invasive 
abilities [91]. Molecularly, this process is accompanied 
with the cell junction switch from E-Cadherin to 
N-Cadherin [92, 93]. TGF-β signaling is known as an 
important molecule to induce EMT in a 
SMAD4-dependent manner through the induction of 
translocation of SMAD2/3/4 complex to the nucleus, 
leading to the expression of mesenchymal markers 
SNAIL, SLUG, TWIST and ZEB [94-96]. When 
knocking down SMAD4 in mammary gland epithelial 
cell NMuMG, the TGF-β induced EMT was potently 
blocked with the failure of E-cadherin reduction and 
N-cadherin induction, as well as morphologic 
transformation [97]. Similarly, SMAD4 knockdown in 
liver significantly reduced liver tumorigenesis 
through upregulating SNAIL, suggesting that TGF-β 
signal promotes EMT in a SMAD4-dependent manner 
[98]. Moreover, TGF-β induced EMT is also inhibited 
by the nuclear factor YY1, which can bind to SMAD 
complex and suppress its transcriptional activity [99, 
100]. These reports reinforce the role of SMAD4 
mediated TGF-β signal in the EMT process. A recent 
study revealed that TGF-β/SMAD4 signal also 
inhibits the transcription of KLF5 through SNAIL. 
With the low KLF5 level, SOX4 is switched from 
tumor promotor to suppressor. Therefore, 
TGF-β/SMAD4 actually induced lethal EMT in PDAC 
[101]. 
TGF-β/SMAD4 in DNA damage response 
and DNA damage repair 
It has been shown that mice carrying specific 
disruption of SMAD4 in head and neck epithelia 
developed head and neck cancer that is associated 
with increased genomic instability and downregulat-
ed expression and function of genes encoding 
proteins in the Fanconi anemia/BRCA (FANC/ 
BRCA) DNA repair pathway [85]. It was also shown 
mice carrying K14-Cre mediated disruption of 
SMAD4 (K14.SMAD4-/-) in keratinocytes suffered 
increased DNA damage and increased susceptibility 
to UV induced carcinogenesis [102]. The skin of the 
K14.SMAD4-/- mice had significantly reduced 
expression of excision repair cross-complementation 
group1 (ERCC1) gene that is correlated with reduced 
ERCC1-mediated DNA repair. Their further study 
demonstrated that SMAD4 deficiency impaired 
SNAIL binding to the ERCC1 regulatory elements, 
leading to the reduced ERCC1 expression. In breast 
cancer cells and primary breast tumor specimens, it 
was found that TGF-β downregulates the expression 
of several genes that are essential for DNA damage 
response (DDR), including ataxia telangiectasia- 
mutated (ATM), mutS homolog 2 (MSH2), and 
BRCA1 [103, 104]. Through downregulating these 
genes, TGF-β attenuates DDR in these breast 
cancer cells and enables them to escape the DNA 
damage checkpoint, allowing their proliferation in the 
presence of unrepaired DNA damage. Thus, 
TGF-β/SMAD4 signaling plays an important role in 
maintaining DDR and DNA damage repair through 
regulating transcription and activity of some key 
genes involved in these processes. This may be one of 
the main mechanisms through which TGF-β/SMAD4 
signaling suppresses tumor formation and growth. 
TGF-β/SMAD4 and microRNA 
 Recent studies revealed that another important 
function of TGF-β/SMAD4 signaling is in regulation 
of microRNA. It has been shown that TGF-β1 was able 
to induce miR-574-3p transcription in gastric cancer 
cell AGS to inhibit cell proliferation, which was 
dependent on the binding of SMAD4 to the promotor 
of miR-574-3p [105]. Moreover, TGF-β/SMAD4 
signaling could induce a set of microRNAs in human 
hepatocellular carcinoma cell Huh-7. The transcri-
ption of miR-23a∼27a∼24 was upregulated quickly 
upon TGF-β treatment, and attenuated by SMAD4 
deletion [106]. On the other hand, SMAD4 is also 
subject to regulation by microRNA. In colon cancer 
cells and tumor specimens, the upregulated 
miR-19b-3p directly targets SMAD4 to attenuate 
proliferation and sensitivity to oxaliplatin-based 
chemotherapy [107]. Besides miR-19b-3p, SMAD4 is 
also the target of some other microRNAs. For 
example, miR-27a, which is induced in human 
lymphatic endothelial cells (HLECs) by co-culturing 
with colon tumor cells, directly targetes SMAD4 and 
promotes lymphangiogenesis [108]. 
TGF-β/SMAD4 and cancer prognosis 
Although the molecular mechanism of SMAD4 
in carcinogenesis is still not clear, the alteration in 
types of cancers are studied exclusively, especially in 
pancreatic adenocarcinoma (Table 2). Wilentz et al 
(2000) studied 41 xenografted primary periampullary 
adenocarcinomas for the correlation between SMAD4 
expression and prognosis [109]. Immunohistoche-
mical staining of SMAD4 showed 22 cases were 
negative, accounting for 56% of the patients. The 
survival analysis revealed that the patients with 
positive SMAD4 signal lived longer than those with 
negative signal, with the median survival of 16.5 
months versus 9 months. Recently, Singh’s group 
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focused on an Indian population with pancreatic duct 
adenocarcinoma for SMAD4 alteration and effect of 
its loss on patient survival [110]. The SMAD4 gene 
was altered by homozygous deletion in 5 patients and 
intragenic mutation in the MH2 domain in 3 patients, 
together accounting for 32% of the patients. The 
follow-up investigation provided a median survival 
of 5 months in the SMAD4 alteration group while 10 
months in the SMAD4 wildtype group. Many other 
reports, as summarized in table 2, show the similar 
outcome in pancreatic duct adenocarcinoma.  
SMAD4 expression level has a positive 
correlation with survival in colon cancer, and the loss 
of SMAD4 leads to poor prognosis [111]. 
Additionally, SMAD4 is also correlated with tumor 
metastasis [112]. A study involving 202 colorectal 
cancer patients revealed that cases with normal 
SMAD4 expression benefit from 5-fluorouracil based 
chemotherapy at a 3-fold higher improvement than 
those with SMAD4 loss [113]. These studies suggest 
that SMAD4 loss may predict poor outcome for 
5-fluorouracil therapy in patients with colorectal 
cancer.  
Recent studies indicated that SMAD4 could be a 
prognostic factor together with other genes. Through 
evaluating the expression level of SMAD4 and PTEN 
in patients bearing colorectal cdenocarcinoma, there 
was a significant difference in the overall survival, 
showing patients with loss of both SMAD4 and PTEN 
had worse outcome than cases with SMAD4 or PTEN 
loss alone [114]. Moreover, another study showed the 
patients with wildtype SMAD4 and KRAS had twice 
longer survival than those bearing SMAD4 loss and 
KRAS actication (83.8 vs. 36.7 months) [115]. 
Conclusion and perspective 
Numerous studies during passed two decades 
provide strong evidence that SMAD4 is a tumor 
suppressor, whose mutations are found in at least 26 
types of cancer, with higher frequencies in GI tract 
cancers, such as Esophagus, Stomach, pancrease and 
Colorectal cancers (Table 1). Additionally, loss of 
SMAD4 in tumors affects cancer progression and 
therapy, such as reduced response to adjuvant 
chemotherapy [116]. SMAD4 plays its function 
through acting as the central mediator for canonical 
TGF-β signaling pathway, and affects tumorigenesis 
through numerous mechanisms, such as inducing cell 
cycle arrest, apoptosis, EMT, and others. Thus, 
SMAD4 not only functions as a tumor suppressor, but 
also may serve as a prognostic indicator. 
 Even though the SMAD4 mediated TGF-β 
signaling pathway has been elucidated well, how 
SMAD4 alteration causes tumor formation and 
progression remains unclear due to the crosstalk with 
other pathways. For example, although SMAD4 is 
highly deleted in human pancreatic cancer, the mouse 
with SMAD4 deficiency in pancreas dose not develop 
a tumor, suggesting additional mutations may be 
required. Owing to the technology limitation, only a 
few genes, such as APC in colorectal cancer and PTEN 
in pancreatic cancer and cholangiocarcinoma, are 
currently identified. Fortunately, the recent 
well-developed CRISPR knockout library provides 
the opportunity to screen these SMAD4 synergistic 
genes at genome-scale level. Therefore, we can 
anticipate the discovery of more such genes. 
Moreover, the CRISPR knockout library can also be 
used to screen drug resistant or sensitive genes on the 
genetic background of SMAD4 deficiency, as the 
SMAD4 loss is reported to predict poor outcome for 
chemotherapy, such as 5-fluorouracil therapy in 
patients with colorectal cancer [113]. 
Although limited knowledge is availabale 
regarding the mechanism, some molecules associated 
to SMAD4, including UA62001 and UA62784, have 
been developed as candidates in cancer treatment [71, 
117]. With the discovery of new components that 
could facilitate SMAD4 associated tumor progression 
and resistant genes in SMAD4 associated insensitivity 
to drugs, more and more SMAD4 associated 
molecules can be the potent target for cancer 
treatment. 
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